Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

New trial on home oxygen therapy for patients with chronic heart failure

Researchers at the University of Hull, in the UK, have just launched a major new trial investigating the effects of home oxygen therapy in patients with chronic heart failure (CHF).

21 May 2012

Dyspnea limits sexual activity among older patients with COPD

Troublesome dyspnea that limits sexual activity is common among older patients with COPD, according to a new study from Denmark.

21 May 2012

SERVE-HF study on effect of CSA treatment for stable heart failure enrolls 1,000th participant

SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.

From ResMed Corp 21 May 2012

Study investigates link between BMI and cardiac function in obese adolescents

Obese adolescents with no symptoms of heart disease already have heart damage, according to new research.

21 May 2012

Nordic walking enables heart failure patients to exercise more intensely

Nordic walking enables heart failure patients to exercise more intensely than walking without poles.

21 May 2012

Statin therapy prevents cancer and reduces death risk in heart transplant recipients

Statins prevent cancer and reduce death from all causes in heart transplant recipients. The findings were independent of cholesterol levels.

21 May 2012

Final results from C3BS-CQR-1 Phase II trial on heart failure

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.

19 May 2012

Positive results from CardioKinetix Parachute system study on heart failure

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced two-year clinical results for the first-of-its-kind catheter-based Parachute Ventricular Partitioning Device, a Percutaneous Ventricular Restoration (PVR) therapy for patients with ischemic heart failure.

19 May 2012

UK-led technologies set to transform treatments on the NHS

Video games, pioneering gene therapies and new medical devices are set to transform treatments on the NHS, with support from the Department of Health and the Wellcome Trust.

19 May 2012

Urocortin 2 improves cardiac output in Phase II study for acute decompensated heart failure

Neurocrine Biosciences, Inc. today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated heart failure. The UNICORN study was conducted over approximately a two year period by the Cardioendocrine Research Group from the University of Otago in Christchurch, New Zealand and included patients admitted to Christchurch Hospital with acute decompensated heart failure.

18 May 2012

Fitness fanatic dad becomes research pioneer after kidney disease diagnosis

A super-fit father who rowed the distance from the Equator to the North Pole on a rowing machine has told of how his experience of kidney disease led to him becoming the first patient to take part in a groundbreaking research study run in Sheffield and Leeds.

17 May 2012

Colleagues In Care, IBM partner to help improve healthcare delivery in Haiti

IBM today announced it is helping improve healthcare delivery in Haiti through its collaboration with 'Colleagues In Care' Global Health Network.

17 May 2012

PPCI treatment on the rise among Stent for Life Initiative participants

Life saving primary percutaneous coronary intervention (PPCI) treatment is increasing in countries participating in the Stent for Life Initiative.

17 May 2012

Death risk for marathon runners remains low during or soon after race

Even though hundreds of thousands more people finished grueling 26.2 mile marathons in the United States in 2009 compared to a decade earlier, a runner’s risk of dying during or soon after the race has remained very low — about .75 per 100,000, new Johns Hopkins research suggests. Men, however, were twice as likely to die as women.

16 May 2012

Palpitations, hypertension strongest risk factors for AF

A large cohort study has found that the strongest risk factors for atrial fibrillation in both men and women were a history of palpitations and hypertension. While hypertension is a well known risk factor for AF, the investigators note that "the impact of self-reported palpitations on later occurrence of AF has not been documented earlier".

16 May 2012

Nile reports net operating loss of $0.8M for first quarter 2012

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its first quarter financial results for 2012.

16 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.

16 May 2012

Biogen Idec announces availability of two new AVONEX dosing innovations for MS

Biogen Idec announced that two new dosing innovations designed to help patients receiving once-a-week AVONEX (interferon beta-1a) for relapsing forms of multiple sclerosis (MS) are now available in U.S. pharmacies.

15 May 2012